Posted on 30/11/2009 in Scientific IDS has published its latest interim financial results for the six months to September 30th 2009.
The company revealed that its revenue rose by 56 per cent to 16.9 million pounds throughout the period, compared to the 10.8 million pounds recorded during the same time in 2008.
Additionally, its gross profit increased from 6.5 million pounds during the correlating time last year to 12.3 million pounds in 2009 - representing a rise of 88 per cent.
Sales of its flagship vitamin D products were also found to have risen by 104 per cent on a year-on-year basis.
David Evans, chairman of IDS, stated that trading for the period was in line with the expectations of the company's management.
"Overall, the prospects for the group remain bright and we continue to forge ahead with our plans for growth both organically and where we may deem it appropriate by acquisition," he continued.
IDS, which was founded in 2003, is headquartered in the UK and specialises in the development of immunoassay kits for the determination of vitamin D.
Other news stories from 30/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
